Is Preclinical Autoimmunity Benign?

Majka, Darcy S.; Chang, Rowland W.

doi:10.1016/j.rdc.2014.07.006

Cited by 17 publications

(9 citation statements)

References 62 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, most of the benefits of moderate alcohol consumption have been described in the context of cardiovascular disease32. Here, we revealed that cardiovascular diseases were associated with increased prevalence of tissue non-specific autoantibodies, regardless of whether the person was consuming alcohol or not, which has been suggested previously33. Surprisingly, these associations were revealed in men and were not significant in women.…”

Section: Discussionsupporting

confidence: 73%

Demographic associations for autoantibodies in disease-free individuals of a European population

Haller-Kikkatalo

Alnek

Metspalu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

The presence of autoantibodies usually precedes autoimmune disease, but is sometimes considered an incidental finding with no clinical relevance. The prevalence of immune-mediated diseases was studied in a group of individuals from the Estonian Genome Project (n = 51,862), and 6 clinically significant autoantibodies were detected in a subgroup of 994 (auto)immune-mediated disease-free individuals. The overall prevalence of individuals with immune-mediated diseases in the primary cohort was 30.1%. Similarly, 23.6% of the participants in the disease-free subgroup were seropositive for at least one autoantibody. Several phenotypic parameters were associated with autoantibodies. The results suggest that (i) immune-mediated diseases are diagnosed in nearly one-third of a random European population, (ii) 6 common autoantibodies are detectable in almost one-third of individuals without diagnosed autoimmune diseases, (iii) tissue non-specific autoantibodies, especially at high levels, may reflect preclinical disease in symptom-free individuals, and (iv) the incidental positivity of anti-TPO in men with positive familial anamnesis of maternal autoimmune disease deserves further medical attention. These results encourage physicians to evaluate autoantibodies in addition to treating a variety of patient health complaints to detect autoimmune-mediated disease early.

show abstract

Section: Discussionsupporting

confidence: 73%

Demographic associations for autoantibodies in disease-free individuals of a European population

Haller-Kikkatalo

Alnek

Metspalu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“… 26 It is therefore possible that subclinical autoimmunity may result in subclinical atherosclerosis and either can manifest itself clinically as the initial clinical presentation. 27 Alternatively, the two mechanisms, autoimmunity and atherosclerosis, may develop independently but concurrently and may manifest themselves clinically at different times. This may be due to either a common genetic predisposition to both conditions or independent genetic factors interacting through epigenetic or environmental influences.…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort

et al. 2016

View full text Add to dashboard Cite

ObjectiveTo describe the frequency of myocardial infarction (MI) prior to the diagnosis of systemic lupus erythematosus (SLE) and within the first 2 years of follow-up.MethodsThe systemic lupus international collaborating clinics (SLICC) atherosclerosis inception cohort enters patients within 15 months of SLE diagnosis. MIs were reported and attributed on a specialised vascular event form. MIs were confirmed by one or more of the following: abnormal ECG, typical or atypical symptoms with ECG abnormalities and elevated enzymes (≥2 times upper limit of normal), or abnormal stress test, echocardiogram, nuclear scan or angiogram. Descriptive statistics were used.Results31 of 1848 patients who entered the cohort had an MI. Of those, 23 patients had an MI prior to SLE diagnosis or within the first 2 years of disease. Of the 23 patients studied, 60.9% were female, 78.3% were Caucasian, 8.7% black, 8.7% Hispanic and 4.3% other. The mean age at SLE diagnosis was 52.5±15.0 years. Of the 23 MIs that occurred, 16 MIs occurred at a mean of 6.1±7.0 years prior to diagnosis and 7 occurred within the first 2 years of follow-up. Risk factors associated with early MI in univariate analysis are male sex, Caucasian, older age at diagnosis, hypertension, hypercholesterolaemia, family history of MI and smoking. In multivariate analysis only age (OR=1.06 95% CI 1.03 to 1.09), hypertension (OR=5.01, 95% CI 1.38 to 18.23), hypercholesterolaemia (OR=4.43, 95% CI 1.51 to 12.99) and smoking (OR=7.50, 95% CI 2.38 to 23.57) remained significant risk factors.ConclusionsIn some patients with lupus, MI may develop even before the diagnosis of SLE or shortly thereafter, suggesting that there may be a link between autoimmune inflammation and atherosclerosis.

show abstract

“…Autoantibodies are also increasingly identified as pathogenic in new ways beyond their role in classic AIDs. For example, autoantibodies have been identified as a potential cause of heart or lung disease in adults and may participate in the process of atherosclerosis [15][16][17][18][19][20][21]. A number of maternal autoantibodies show person-to-person transmission of disease to the developing fetus during pregnancy and may have adverse effects, the most outstanding is of these being neonatal lupus, neonatal thyroid disease and thyroid autoantibody related early fetal loss and pre-term birth [22][23][24][25][26][27].…”

Section: Introductionmentioning

confidence: 99%

Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960–2014

2020

View full text Add to dashboard Cite

ObjectiveBased on US National Health and Nutrition Examination Survey (NHANES) data, we attempted to provide an unbiased, population-based estimate of autoantibody prevalence overall and by age and sex. MethodsUS autoantibody prevalence estimates for detectable rheumatoid factor, anti-thyroglobulin, anti-thyroperoxidase, anti-transglutaminase, anti-endomysial, anti-GAD65, antinuclear autoantibodies, and autoantibodies to extractable nuclear antigens were estimated from the 1960-1962 National Health Examination Survey, NHANES III (1988, and the NHANES 1999-2014 cross-sectional surveys. Survey design variables and sample weights were used to account for differential probabilities of selection within the complex survey design. Data analysis used SAS TM and SUDAAN™ software. US Census Bureau data were used to estimate the absolute numbers of persons with autoantibodies.

show abstract

Is Preclinical Autoimmunity Benign?

Cited by 17 publications

References 62 publications

Demographic associations for autoantibodies in disease-free individuals of a European population

Demographic associations for autoantibodies in disease-free individuals of a European population

Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort

Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960–2014

Contact Info

Product

Resources

About